Based on the correlations between EZH2 and chemoresistance, a phase 1/2 trial (NCT03879798) is assessing the safety and efficacy of the EZH1/2 inhibitor DS-3201b in combination with irinotecan for patients with recurrent SCLC. The gene discussed is EZH2; the disease is small cell lung carcinoma.